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Abstract
Background
Diagnostic trajectories for neurogenetic disorders frequently require the use of considerable
time and resources, exposing patients and families to so-called “diagnostic odysseys”. Pre-
vious studies have provided strong evidence for increased diagnostic and clinical utility of
whole-exome sequencing in medical genetics. However, specific reports assessing its utility
in a setting such as ours- a neurogeneticist led academic group serving in a low-income
country—are rare.
Objectives
To assess the diagnostic yield of WES in patients suspected of having a neurogenetic condi-
tion and explore the cost-effectiveness of its implementation in a research group located in
an Argentinean public hospital.
Methods
This is a prospective study of the clinical utility of WES in a series of 40 consecutive patients
selected from a Neurogenetic Clinic of a tertiary Hospital in Argentina. We evaluated
patients retrospectively for previous diagnostic trajectories. Diagnostic yield, clinical impact
on management and economic diagnostic burden were evaluated.
Results
We demonstrated the clinical utility of Whole Exome Sequencing in our patient cohort,
obtaining a diagnostic yield of 40% (95% CI, 24.8%-55.2%) among a diverse group of neuro-
logical disorders. The average age at the time of WES was 23 (range 3–70). The mean time
elapsed from symptom onset to WES was 11 years (range 3–42). The mean cost of the
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diagnostic workup prior to WES was USD 1646 (USD 1439 to 1853), which is 60% higher
than WES cost in our center.
Conclusions
WES for neurogenetics proved to be an effective, cost- and time-saving approach for the
molecular diagnosis of this heterogeneous and complex group of patients.
Introduction
Neurogenetic disorders are a frequent reason for medical consultation in neurology services.
Clinical variability and genetic heterogeneity are a hallmark of these diseases. Their diagnostic
approach requires extensive clinical, radiological and genetic evaluations. Moreover, many of
these procedures are invasive and costly. However, despite the use of considerable time and
resources, the diagnostic yield in this field has been disappointingly low. This etiologic search
has been called a “diagnostic odyssey” for many families [1].
Whole Exome Sequencing (WES) has proved to be a valuable tool in medical genetics, for
diagnostic and gene discovery purposes [2–4]. Although a diagnostic yield of about 30% in
neurogenetic disorders can be extrapolated from the results of large series that have included
other medical conditions as well [5], specific reports assessing its utility in a setting such as
ours—a neurogeneticist led academic group serving in a low-income country—are rare. There-
fore, there is still a necessity to assess its clinical utility and the feasibility of its implementation
for neurogenetic diagnostic practice in less economic favorable locations where rational and
effective use of resources is both an obligation and an opportunity for reducing inequalities [6,
7].
We are reporting here on our first 40 consecutive cases which were selected from our
research-based laboratory for WES. We demonstrated the clinical utility of WES and the
potential cost-effectiveness of WES as a single test by examining the number and types of tests
that were performed prior to WES that add to the cost of diagnostic workups.
Materials and methods
Clinical samples
We included a consecutive series of 40 patients selected for WES from a Neurogenetic Clinic
of a tertiary Hospital in Argentina. These patients were considered candidates for genomic
studies according to the presence of typical findings of known neurogenetic diseases and/or
hints of monogenic etiology such as familial aggregation or chronic and progressive course.
We recorded perinatal and family history, likely inheritance model/s, disease progression char-
acteristics, comorbidities, and studies performed before WES from each patient of our cohort.
The diverse clinical features of this cohort are summarized in Table 1. Written informed Con-
sent for WES was obtained from the patients and/or their family. The informed consent
included the option to receive or not incidental findings according to ACMG recommenda-
tions. Internal review board (IRB) approval was obtained at Hospital JM Ramos Mejia. All
methods were performed in accordance with the relevant guidelines and regulations.
Whole exome sequencing in neurogenetic odysseys
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Table 1. Demographic characteristics and clinical features of patients selected for WES ().
CASE
ID
AGE OF
ONSET
AGE AT
TESTING
PRIMARY DISEASE
CLASSIFICATION
CLINICAL PRESENTATION
1 1 28 - Mental retardation, autism, epilepsy, dystonia
2 5 9 Epilepsy with Variable Foci Epilepsy
3 1 5 Dravet Syndrome Epilepsy, cognitive impairment
4 9 17 Hemiplegic Migraine Episodic migraine, hemiplegia
5 14 24 Sporadic ataxia Ataxia, myoclonus, cognitive impairment, cerebellar atrophy on MRI
6 9 24 Spastic Paraplegia Plus Paraplegia, mental retardation, thinning of the corpus callosum on MRI, peripheral
neuropathy
7 4 23 - Generalized dystonia, chorea, cognitive impairment
8 2 5 Epileptic encephalopathy Ataxia, absence epilepsy, neurodevelopmental delay
9 8 50 Myopathy Very mild muscle weakness, hyperCKemia
10 1 11 Epileptic encephalopathy Autism, hyperactivity, epilepsy
11 6 11 Ataxia + oculomotor apraxia Ataxia, chorea, tremor, oculomotor apraxia
12 16 23 Leukodystrophy leukodystrophy on MRIs + cognitive impairment Ataxia + pyramidal syndrome
+ abnormal eye movements
13 55 70 Sporadic ataxia Ataxia
14 1 4 Leigh syndrome Developmental delay, refractory epileptic encephalopathy, MRI signal abnormalities in
the basal ganglia
15 11 22 Mitochondrial Disorder Muscle fatigue
16 1 5 Chain respiratory disorder Developmental delay, recurrent vomiting
17 29 54 Sporadic ataxia Ataxia, pyramidal.
18 5 15 Ataxia Ataxia, neuropathy, cerebellar atrophy
19 2 12 - Developmental Disorder, speech impairment, polyneuropathy
20 42 53 Sporadic ataxia Ataxia, cerebellar atrophy
21 3 11 Epileptic encephalopathy Partial seizures, ataxia
22 Neonatal 3 Neonatal adrenoleukodystrophy Hepatic dysfunction, hypotonia, white matter lesions on MRI
23 Neonatal 3 Encephalopathy Mental delay, physical growth retardation, diarrhea, vomiting and increased lactic acid
24 Neonatal 9 Encephalopathy Developmental delay, seizures, muscular weakness, dystonia. Fragmentary hypo
myelination on MRI
25 30 52 Episodic ataxia Episodic ataxia
26 12 23 Leukodystrophy Ataxia, cognitive impairment, abnormal ocular movements. Symmetric hypo
myelination on MRI
27 27 33 Rhabdomyolysis Rhabdomyolysis, muscular fatigue
28 6m 5 Mitochondrial Developmental delay, epilepsy, dystonia, ragged red fibers on muscular biopsy
29 3 32 Myopathy Proximal muscular weakness, muscular atrophy
30 Neonatal 8 Congenital disorder of Glycosylation Microcephaly, seizures, muscular weakness
31 Neonatal 10 Polymicrogyria Seizures, polymicrogyria on MRI
32 2 8 - Speech impairment, developmental delay
33 18m 31 Spastic quadriplegia Quadriplegia, pyramidal dysfunction, fasciculation, muscular atrophy
34 50 58 Ataxia / Dementia Progressive multidomain cognitive impairment, ataxia
35 6m 5 Myopathy Developmental delay, hypotonia, muscular weakness
36 8 19 Dystonia Generalized dystonia
37 2 16 Optic Neuropathy Progressive visual loss
38 41 53 Sensory Ataxia Ataxia, distal hypoesthesia
39 6 17 NBIA Dystonia, tremor
40 46 56 Sub-acute Dementia-Movement
Disorders
Behavioral disorders, tremor, bradykinesia
36 patients were selected for WES based on the presence of a well-defined clinical syndrome; the first-tier analysis was done by investigating a panel of known disease
genes known to be associated with the respective condition. The rest represents complex phenotypes with overlapping neurological features. The mean age at WES was
23, ranging from 3–70 years. (Age at testing column)
The mean time between the disease onset and WES was 11.5 years (range 3–42).
https://doi.org/10.1371/journal.pone.0191228.t001
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Whole exome sequencing and sanger confirmation
Genomic DNA was isolated from blood samples of each subject with the use of commercial
kits. DNA sequencing libraries were constructed mostly by chemical fragmentation using
commercial preparation kits. Exomes were enriched using different systems, being the vast
majority of our cases processed with SureSelect Human All Exon v4 Kits (Agilent Technolo-
gies, Santa Clara, CA, USA). NGS sequencing runs were made in Illumina HiSeq 2500 systems
as an outsourced service from Macrogen Inc (Korea) obtaining an average sequence coverage
of more than 70X, with more than 97% of the target bases having at least 10X coverage. All
standardized procedures were performed according to manufacturer’s instructions that have
been widely mentioned in the literature [8, 9]. Clinically relevant variants, from proband and
parental samples (whenever available), were confirmed by Sanger sequencing.
Data analysis and annotation
Sequence data in FastQ format were aligned to the human reference genome (GRCh37) using
the Burrows-Wheeler Alignment Tool (BWA-MEM) [10]. Variants Calls were generated using
GATK haplotype caller following the so called best practices [11]. The output vcf file was anno-
tated at various levels using Annovar [12] (S1A Fig). Variants were prioritized according to
inheritance model, population frequency, molecular function and effects of mutations,
reported clinical effect, and optionally according to a list of genes associated with the disease
under study. In that sense two in-house protocols were defined. One “molecular hypothesis
free”, for patients presenting complex phenotypes without candidate genes. Another “molecu-
lar hypothesis targeted” for patients that shows a defined clinical syndrome with available can-
didate genes. (S1B Fig). Classification of variants followed previously published schemes [13]
updated with recent recommendations and guidelines by the American College of Medical
Genetics and Genomics and the Association for Molecular Pathology [14]. Joining variant
level and clinical features information, we classified each WES study as positive if a patho-
genic/likely pathogenic mutation in known disease gene was identified with positive phenotypic
and inheritance overlap; undetermined if a pathogenic/likely pathogenic mutation in a putative
candidate gene was identified with positive phenotypic and inheritance overlap or only one patho-
genic/likely pathogenic mutation was identified with positive phenotypic overlap in a recessive dis-
order and negative in the rest of the cases. We paid special attention to reviews of previous
work done in cases studied before the 2015 update, reanalyzing them according to the new
schema. Details for each novel variant are presented in S1 Table.
Incidental findings were informed according to ACMG recommendations. Counseling to
patients was performed by trained professionals.
Results
WES proved to be an effective, cost- and time-saving diagnostic approach in our setting. Six-
teen WES satisfied criteria for a full molecular diagnosis (Table 2 and S1 Table), thus the over-
all diagnostic yield for WES in our series was 40% (S2 Fig, Yield). Among them, two WES
were reclassified from original undetermined and negative categories after subsequent reanaly-
sis identified pathogenic variants in genes not associated with human disorders at the time of
original reports. A diverse group of neurological disorders were represented in the positive
patients (Table 2). The average age at the time of WES was 23 (3–70). The mean time elapsed
from symptom onset to WES was 11 years (range 3–42). The positive group included 9 patients
with autosomal dominant disease and 7 with autosomal recessive disease. Different mutation
types were observed in this cohort. Noteworthy, 56% of the mutations were novel, according
to ExAC v3 database [9] (Fig 1). Although almost all of the molecular diagnoses were in
Whole exome sequencing in neurogenetic odysseys
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Table 2. Summary of patients with established molecular diagnosis by WES.
CASE
ID
GENE PHENOTYPE OMIM
Entry
INHERITANCE/
SEGREGATION
MUTATION(S) LITERATURE TYPE OF
MUTATION
ALTERED
MANAGEMENT
1 () GRIK2 Mental Retardation, autism,
epilepsy, dystonia
611092 Recessive (Both
parents
inheritance)
NM_021956.4:c592C>T;
p.R198X Hom
(Motazacker
MM et al. 2007)
nonsense
2 DEPDC5 Epilepsy with Variable Foci 604364 Dominant
(paternal
inheritance)
NM_001242896:
c.4718T>C;p.L1573P
(Baulac et al.
2014)
missense
4 CACNA1A Hemiplegic Migraine 141500 Sporadic (De
novo)
NM_000068:c.3675C>A;
p.F1225L
(Riant et al.
2010)
missense
5 () STUB1 Sporadic Ataxia 607207 Sporadic (Both
parents
inheritance)
NM_005861.2:c.612+1 G>
C; p.? NM_005861.2:
c.823C>G;L275V
(Shi et al. 2014) splicing/
missense
Endocrine
monitoring to
evaluate appearance
of hypogonadism
6 SPG11 Paraplegia, mental
retardation, thinning of the
corpus callosum peripheral
neuropathy
604360 Sporadic (Both
parents
inheritance)
NM_025137:c.6763insA; p.
L2255Hfsx85
NM_025137:6726A>T; p.
Q2242H;
(Stevanin et al.
2007)
Frameshift/
missense
L-Dopa Trial
8 KCNA2 Ataxia, early absence
epilepsy,
neurodevelopmental delay
616366 Sporadic (De
novo)
NM_001204269::c.G890A:
p.R297Q (a)
(Syrbe et al.
2015)
missense Acetazolamide and
Fampridine Trial
9 DMD Myopathy with very mild
muscle weakness,
hyperCKemia
300377 Sporadic NM_004006.2:c.1149
+1C>A (b) Het
(Carsana et al.
2010)
splicing Avoid Statins
11 APTX Ataxia, chorea, tremor,
oculomotor apraxia
208920 Recessive (Both
parents
inheritance)
NM_175069.1:c.879G>A;
p.W293X (c) Hom
(Shimazaki
et al. 2002)
nonsense Ubiquinone Trial
21 PCDH19 Epileptic encephalopathy
with partial seizures and
ataxia
300088 Sporadic (paternal
inheritance)
NM_001184880:exon1:c.
T1151G:p.V384G
(Hynes et al.
2010)
nonsense
22 PEX12 Neonatal
adrenoleukodystrophy with
hepatic dysfunction,
hypotonia, white matter
lesions on MRI
266510 Sporadic (Both
parents
inheritance)
NM_000286:
c.733_734insGCC;p.
L245Cfsx19 (d)
NM_000286:c.533_535del:
p.Q178del (e)
(Gootjes et al.
2004)
Frameshift/
nonframeshift
26 POLR3A Leukodystrophy with
ataxia, cognitive
impairment, abnormal
ocular movements and
symmetric hypo
myelination on MRI
607694 Recessive (Both
parents
inheritance)
NM_007055.3:c.3781G>A;
p.Q1261KNM_007055.3:
c.3014G>A;p.R1005H (f)
(Wolf et al.
2014)
Missense/
missense
28 MT-ATP6 Mitochondrial disease with
ddevelopmental delay,
epilepsy, dystonia, ragged
red fibers on muscular
biopsy
551500 Mitochondrial m.T8993G (g) (Holt et al.
1990)
missense Avoid drugs with
mitochondrial
toxicity
29 SGCG Myopathy with proximal
muscular weakness,
muscular atrophy
608896 Sporadic (both
parents
inheritance)
NM_000231: c.521delT:p.
F175LfsX20 (h) Hom
(Lasa et al.
1998)
frameshift
30 GNAO1 Glycosylation congenital
disorder with microcephaly,
seizures, muscular
weakness
615473 Sporadic (De
novo)
NM_020988: c.709G>A:p.
Q237K
(Nakamura
et al. 2013)
missense
33 ALS2 Spastic quadriplegia,
pyramidal dysfunction,
fasciculation, muscular
atrophy
607225 Sporadic (both
parents
inheritance)
NM_020919: c.T2531A: p.
L844H Hom
(Eymard-Pierre
et al. 2006)
missense
(Continued)
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Table 2. (Continued)
40
()
ATP7B Sub-acute Dementia with
movement Disorders
277900 Recessive (Both
parents
inheritance)
NM_000053: c.2165T>A:
p.L722Q NM_000053:
c.3704G>A: p.G235N
(Takeshita et al.
2002)
Missense/
missense
Treatment with
Penicilamine
CASE
ID
GENE PHENOTYPE OMIM
Entry
INHERITANCE/
SEGREGATION
MUTATION(S) LITERATURE TYPE OF
MUTATION
ALTERED
MANAGEMENT
1 () GRIK2 Mental Retardation, autism,
epilepsy, dystonia
611092 Recessive (Both
parents
inheritance)
NM_021956.4:c592C>T;
p.R198X Hom
(Motazacker
MM et al. 2007)
nonsense
2 DEPDC5 Epilepsy with Variable Foci 604364 Dominant
(paternal
inheritance)
NM_001242896:
c.4718T>C;p.L1573P
(Baulac et al.
2014)
missense
4 CACNA1A Hemiplegic Migraine 141500 Sporadic (De
novo)
NM_000068:c.3675C>A;
p.F1225L
(Riant et al.
2010)
missense
5 () STUB1 Sporadic Ataxia 607207 Sporadic (Both
parents
inheritance)
NM_005861.2:c.612+1 G>
C; p.? NM_005861.2:
c.823C>G;L275V
(Shi et al. 2014) splicing/
missense
Endocrine
monitoring to
evaluate appearance
of hypogonadism
6 SPG11 Paraplegia, mental
retardation, thinning of the
corpus callosum peripheral
neuropathy
604360 Sporadic (Both
parents
inheritance)
NM_025137:c.6763insA; p.
L2255Hfsx85
NM_025137:6726A>T; p.
Q2242H;
(Stevanin et al.
2007)
Frameshift/
missense
L-Dopa Trial
8 KCNA2 Ataxia, early absence
epilepsy,
neurodevelopmental delay
616366 Sporadic (De
novo)
NM_001204269::c.G890A:
p.R297Q (a)
(Syrbe et al.
2015)
missense Acetazolamide and
Fampridine Trial
9 DMD Myopathy with very mild
muscle weakness,
hyperCKemia
300377 Sporadic NM_004006.2:c.1149
+1C>A (b) Het
(Carsana et al.
2010)
splicing Avoid Statins
11 APTX Ataxia, chorea, tremor,
oculomotor apraxia
208920 Recessive (Both
parents
inheritance)
NM_175069.1:c.879G>A;
p.W293X (c) Hom
(Shimazaki
et al. 2002)
nonsense Ubiquinone Trial
21 PCDH19 Epileptic encephalopathy
with partial seizures and
ataxia
300088 Sporadic (paternal
inheritance)
NM_001184880:exon1:c.
T1151G:p.V384G
(Hynes et al.
2010)
nonsense
22 PEX12 Neonatal
adrenoleukodystrophy with
hepatic dysfunction,
hypotonia, white matter
lesions on MRI
266510 Sporadic (Both
parents
inheritance)
NM_000286:
c.733_734insGCC;p.
L245Cfsx19 (d)
NM_000286:c.533_535del:
p.Q178del (e)
(Gootjes et al.
2004)
Frameshift/
nonframeshift
26 POLR3A Leukodystrophy with
ataxia, cognitive
impairment, abnormal
ocular movements and
symmetric hypo
myelination on MRI
607694 Recessive (Both
parents
inheritance)
NM_007055.3:c.3781G>A;
p.Q1261KNM_007055.3:
c.3014G>A;p.R1005H (f)
(Wolf et al.
2014)
Missense/
missense
28 MT-ATP6 Mitochondrial disease with
ddevelopmental delay,
epilepsy, dystonia, ragged
red fibers on muscular
biopsy
551500 Mitochondrial m.T8993G (g) (Holt et al.
1990)
missense Avoid drugs with
mitochondrial
toxicity
29 SGCG Myopathy with proximal
muscular weakness,
muscular atrophy
608896 Sporadic (both
parents
inheritance)
NM_000231: c.521delT:p.
F175LfsX20 (h) Hom
(Lasa et al.
1998)
frameshift
30 GNAO1 Glycosylation congenital
disorder with microcephaly,
seizures, muscular
weakness
615473 Sporadic (De
novo)
NM_020988: c.709G>A:p.
Q237K
(Nakamura
et al. 2013)
missense
(Continued)
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nuclear genes, mitochondrial genome sequencing included in the WES test yielded one diag-
nosis (one individual with a missense mutation in MT-T8993G.
As we mention in methods, a WES study is considered positive if pathogenic or likely patho-
genic variants correspond to the phenotype and the mode of inheritance. We must recognize
that only in case 33, this criterion is not strictly accomplished because the identified variant in
ALS2 must be considered of unknown significance according to last ACMG criteria. However,
we discussed this situation with the referring physician and the patient’s family and decided to
consider the ALS2 variant likely causing the disease, despite acknowledging a higher uncer-
tainty in diagnostic terms. According to this clinical decision, we included this case as a posi-
tive one into this work.
WES were defined as undetermined in two cases (5%). In one of them, we were able to
identify only one pathogenic variant (NM_018082.5:c.1568T>A; p.V523Q) in POLR3B in a
patient showing clinical features consistent with autosomal recessive POLR3-related disorders
[15]. We hypothesize that the second missing allele is a large deletion/insertion or a deep intro-
nic mutation. This case highlights current limitations of WES. In case 17, we found a heterozy-
gous likely pathogenic variant (NM_030954.3:c.668C>A; p.A223N) in RNF170 gene. This
gene was reported as a cause of sensory ataxia [16]. The patient’s phenotype corresponds to
pure cerebellar ataxia.
Table 2 shows a summary of the impact that a definitive diagnosis obtained from WES had
on our patients. The information obtained by means of WES ended the diagnostic odysseys,
led to therapeutic trials in some cases and improved genetic counselling processes with more
precise information.
As an exploratory approach to a monetary cost-analysis of WES in neurogenetic diseases,
we recorded the number and type of complementary tests done by our patients before WES.
The average cost of the “expendable” diagnostic workup prior to WES was USD 1646 (USD
1439 to 1853), which is 60% higher than WES cost in our center (USD 1000). Table 3 shows
that several genetic and non-genetic assays considered unnecessary (e.g. repetitive neuroi-
mages and non-genetic assays) and/or evitable (e.g. recurrent outpatients visits and single-
gene testing) were performed in almost all of our patients. This often-unnecessary repetition
of complementary studies might be a consequence of the extension in time of the so-called
diagnostic odyssey (see before results about time at WES since symptom onset). A more conser-
vative analysis that added up WES cost and stratified the cohort into solved and unsolved cases
showed differences too. The average cost of the diagnostic work up (including WES,
Table 2. (Continued)
33 ALS2 Spastic quadriplegia,
pyramidal dysfunction,
fasciculation, muscular
atrophy
607225 Sporadic (both
parents
inheritance)
NM_020919: c.T2531A: p.
L844H Hom
(Eymard-Pierre
et al. 2006)
missense
40
()
ATP7B Sub-acute Dementia with
movement Disorders
277900 Recessive (Both
parents
inheritance)
NM_000053: c.2165T>A:
p.L722Q NM_000053:
c.3704G>A: p.G235N
(Takeshita et al.
2002)
Missense/
missense
Treatment with
Penicilamine
Dominant inheritance was defined by the presence of an affected parent and recessive inheritance defined by unaffected parents and affected siblings
(a) ClinVar #190328; (b) UMD-DMD France Mutation Database Records 14050 and 18392; (c) ClinVar #4431; (d) and (e) cited in Mol Genet Metab. 2004 Nov;83
(3):252–63; (f) ClinVar #31149; (g) ClinVar #9461; (h) ClinVar #2004;
() Further details were published in Clin Genet. 2015 Mar;87(3):293–5. doi: 10.1111/cge.12423.
() Further details were previously published in Neurology. 2014 Jul 15;83(3):287–8.
() Further details were previously published in Parkinsonism Relat Disord. 2015 Nov;21(11):1375–7.
https://doi.org/10.1371/journal.pone.0191228.t002
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Fig 1. Location and impact of novel variants identified by this study.
https://doi.org/10.1371/journal.pone.0191228.g001
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Table 3. Summary of procedures and visits performed during the Diagnostic Odysseys.
Case
id
CT MRI EMG Biochemical
genetics
Muscle
biopsies
CSF Prior
Genetic
Testing
(all single
gene
testing)
Total number of
unnecessary previous
studies
Number of extra
specialized
outpatient’s visits
Total estimated
expendable
cost (USD)
Total diagnostic
procedures (non-
expendable) (USD)
1 1 2 3 5 2149 2801
2 0 4 1000 2942
3 1 1 3 935 3079
4 2 2 6 2214 1957
5 1 2 1 3 7 4 2913 3171
6 1 1 2 5 1792 2730
7 1 2 3 2 1399 3137
8 0 4 1000 3194
9 1 1 6 1614 2564
10 1 1 8 2357 2237
11 1 1 4 1357 2637
12 1 2 1 4 6 2513 1641
13 1 1 1 3 5 842 4941
14 1 1 4 1357 2871
15 1 1 3 814 3678
16 0 4 1000 3478
17 2 1 3 6 2514 3357
18 2 1 3 5 2264 3221
19 1 1 3 1107 3101
20 2 1 3 2 1157 3314
21 1 1 4 1357 2837
22 2 2 6 2214 2757
23 0 5 1250 3214
24 0 4 1000 3364
25 1 2 3 5 2149 2250
26 1 1 6 1857 2457
27 2 2 7 1978 2443
28 0 6 1500 3178
29 2 1 3 3 1585 2928
30 1 1 6 1857 2478
31 1 1 4 1357 2757
32 1 1 2 7 2292 2387
33 1 3 4 6 2199 3000
34 1 1 4 1114 3000
35 1 1 2 614 3278
36 1 2 4 1357 2757
37 2 2 6 2214 2100
38 1 3 4 1828 2951
39 2 1 3 3 1977 2407
40 1 1 1 3 5 1872 3044
 Only repetitive procedures and visits were considered unnecessary. Thus, only them were summed up for the costs of diagnostic odysseys.
https://doi.org/10.1371/journal.pone.0191228.t003
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expendable and non-expendable procedures) in solved cases was USD 4572 (USD 4302 to
4842), whereas in unsolved cases was USD 4514 (USD 4289 to 4739). Avoiding expendable
procedures, by means of WES, could reduce diagnostic work up expenses in about 39% (USD
2792; 95% CI, USD 2634–2950).
Discussion
Applying WES to a representative sample of 40 patients suffering from neurogenetic diseases,
we obtained an etiologic diagnostic yield of 40%. Furthermore, we were able to expand the
phenotypic spectrum of known genes and identify new pathogenic variants in other genes.
Two cases were illustrative of common themes in medical genomics [17, 18]. A non-sense
mutation in GRIK2 caused a more complex phenotype than it was previously recognized for
this gene. This gene encodes a glutamate receptor and was previously reported once in mem-
bers of a consanguineous family segregating intellectual disability [19]. Our patient also pre-
sented with intellectual disability, epilepsy, dystonia, and behavioral problems of the autism
spectrum [20]. Thus, we were able to extend the phenotypic spectrum associated with this
gene. We also emphasize the finding of a mutation in KCNA2 in a patient with early onset epi-
lepsy and ataxia. This variant was identified after periodic reanalysis of previously non-diag-
nostic WES. Mutations in KCNA2 were recently recognized as the cause of epileptic
encephalopathies and early onset ataxia [21]. This information was unknown at the moment
of the initial analysis, however, being available when this WES was reassessed, it led us to rein-
terpret this case. Recent reports have shown that systematic re-analysis of unsolved WES data
lead to about 10% additional diagnoses [22].
Our preliminary cost-analysis lend support to the assertion made by others that WES is
more cost-effective than other molecular diagnostic approaches based on single- or panel-
gene analysis [2, 3]. However, our estimates ought to be interpreted with caution. The retro-
spective design precludes us to avoid biases during the classification of previous procedures as
unnecessary or evitable. We acknowledge that some of them could certainly be useful for WES
interpretation and should not be considered a complete cost to be saved by WES. Nevertheless,
our findings are similar to other formal analyses in this subject [23], where an early implemen-
tation of WES in the diagnostic trajectory of suspected genetic conditions proves to be cost-
effective by means of a reduction in the number of procedures and specialist visits [24]. More-
over, there are other diagnostic odysseys costs that are harder to represent in monetary terms
but are not less important, such as time lost to the patient and family and quality of life decre-
ment because of this loss. They deserve other type of formal economic studies that could even
show more advantages for the use of WES in the diagnostic approach of complex diseases such
as neurogenetic disorders.
The diagnostic yield in less restrictive adult and pediatric populations series ranged from 17
to 30% [4, 25]. Groups that included only patients showing phenotypes involving the nervous
system reported higher diagnostic yields [26–28]. Our results are comparable with these expe-
riences and highlight the advantages of working as a personalized research group where phe-
notypic and genotypic information can be thoughtfully assessed in contrast to commercial
diagnostic laboratories that only have access to focused, heterogeneous and often less informa-
tive clinical phenotypic reports filled by the external ordering physician. Although undirected
next generation sequencing tests such as WES have proved powerful and useful in the diagno-
sis of several genetic conditions, a targeted approach based on multi-genic panels or even sin-
gle-gene assays is still justified for patients presenting with well-defined phenotypes where a
higher diagnostic yield might be expected because of better coverage and more favorable cost
implications [29]. However, WES have the advantage over more focused approaches, when a
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more comprehensive solution is needed in those patients suffering from genetically and phe-
notypically heterogeneous conditions [30, 31].
WES for neurogenetics proved to be an effective, cost- and time-saving approach for the
molecular diagnosis of this heterogeneous and complex group of patients. It reduces the long
time that these patients must wait before getting a diagnosis thereby ending odysseys of many
years, impacting on their medical management, and optimizing the genetic counseling for
these families. Negative WES still remain a challenge, given the complexity of genomic data
interpretation and the lack of a thorough knowledge of monogenic disorders.
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